Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial
Primary result · Longitudinal DAS28-CRP over 104 weeksResult — go to the resultß −0.204 95% CI −0.486 to 0.078Authors' conclusion
In early insufficient responders, adding etanercept for 6 months did not improve disease control over 104 weeks versus adding leflunomide first.
Study context
- Population
- Treatment-naïve early RA patients started on methotrexate (MTX) + GC bridging (COBRA-Slim), early insufficient responders (Disease Activity Score - C-reactive Protein (DAS28-CRP) >3.2 between W8 and W32 or ≥2.6 at W32)142 early responders not randomised
- Participants
- 55 vs 55
- Comparison
- Adding etanercept for 24 weeks (Bio-induction-CS) vs adding LEF first (Standard-CS) in early insufficient responders to MTX + GC bridging (COBRA-Slim)
- Bio-induction-CSn = 55
- Standard-CSn = 55reference
- Primary endpoint
- Longitudinal disease activity (DAS28-CRP)
- Follow-up
- Over 104 weeks
Methodological detailsopen-label, multicentre, pragmatic, 2-year
- Open-label
- Multicentre
- Pragmatic
- 2-year
Primary result
Longitudinal DAS28-CRP over 104 weeks
ß
−0.204
95% CI −0.486 to 0.078
P = 0.157
As reported in the abstract
Further findings
b/tsDMARD use · W104
| Outcome | Bio-induction-CS | Standard-CS |
|---|---|---|
| DAS28-CRP <2.6 · 28 weeks after randomisation | 59% (95% CI 44%–72%) | 44% (95% CI 31%–59%) |
Original publication
Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial. RMD Open. Published 7 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →